The article focuses on the mechanisms underlying colitis, a severe adverse event associated with cancer immunotherapy using immune checkpoint inhibitors like anti-CTLA-4 antibodies. It mentions the study by Lo et al. reveals that CTLA-4 blockade-induced colitis is dependent on gut microbiota composition, involving unrestrained T cell activation and concurrent depletion of regulatory T cells.